Arginine Deprivation Sustains PD1 Expression via GCN2 to Promote Immune Escape in Multiple Myeloma: A Novel Metabolic and Immune Check-Point

Despite PD-1 inhibitors pembrolizumab and nivolumab are promising agents in hematological malignancies, obejective response in multiple myeloma (MM) is dismal due to the immune-suppressive bone marrow (BM) environment. Our previous work showed that arginine deprivation, due to increased arginase-1 (Arg-1)-positive myeloid-derived-suppressor cells (MDSC), sustains MM progression, but its role in modulating PD1 axis is unknown.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Alessandra Romano, Nunziatina Laura Parrinello, Ugo Orfanelli, Michela Ghizzinardi, Laura Oliva, Matteo Trudu, Piera La Cava, Francesco Di Raimondo, Simone Cenci, Francesca Paradiso, Irene Ingordo, Floriana Cremasco Source Type: research